Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 3 2015


Search Results for 'Drug Discovery'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »

Contract Service Directory Categories

View All Categories »

Search Results:

Published June 3, 2015
Will foster research collaboration with Janssen for development of allogeneic CAR-T therapies Read More »
Published June 3, 2015
New 40,000 sq. ft. facility is the company’s first demonstration lab in the U.S. Read More »
Published June 2, 2015
Bagshaw to lead strategic corporate and business development efforts Read More »
Published June 2, 2015
Selects ARISg as its service platform Read More »
Published June 2, 2015
Expands its CDMO capabilities Read More »
Published June 2, 2015
Will evaluate investigational candidates in cancer patients Read More »
Published May 27, 2015
Bedford to bolster branding and marketing ops post Harlan acquisition Read More »
Published May 21, 2015
Acquires exclusive worldwide rights to SMC technology for research applications Read More »
Published May 19, 2015
Will evaluate combinations of Advaxis’s Lm-LLO immunotherapy technology and Sorrento’s immunomodulatory antibodies Read More »
Published May 14, 2015
Will combine biotech capabilities to develop therapies for autoimmune disorders Read More »
Published May 12, 2015
Will collaborate to identify and validate tumor targets and corresponding TCRs in cancer Read More »
Published May 11, 2015
Firms will co-develop Elasmogen's soloMER technology Read More »
Published May 8, 2015
Beeler brings15 years of experience in the life sciences Read More »
Published May 7, 2015
Will combine biotech capabilities to develop therapies for autoimmune disorders Read More »
Published May 7, 2015
Combines two next-gen discovery platforms Read More »
Published April 30, 2015
Early Discovery acquisitions contribute to growth Read More »
Published April 15, 2015
Will provide discovery and development services from gene to candidates and beyond Read More »
Published April 14, 2015
Batra to lead the combined life science business Read More »
Published April 9, 2015
Will repurpose assets for orphan diseases Read More »
Published April 7, 2015
Enter into license agreement on novel small molecules targeting mTORC1 activation Read More »
Published April 2, 2015
Change over will become official on April 13 Read More »
Published March 26, 2015
Evotec will screen several ion channel targets Read More »
Published March 25, 2015
Will receive as much as £652,000 to expand bioproduction research Read More »
Published March 17, 2015
Clinicians continue to find potential therapeutic indications for Schedule I drug substances Read More »
Published March 17, 2015
Strengthens its T cell receptor cancer gene therapy platform Read More »
Published March 13, 2015
Collaboration related to microbiome discovery and development Read More »
Published March 5, 2015
To provide integrated offering for candidate selection through to early stage trials Read More »
Published February 27, 2015
Goal is to identify best-in-class RORγ inhibitors to treat autoimmune disease Read More »
Published February 25, 2015
Opens newly expanded office Read More »
Published February 20, 2015
To use TBK1 to study ALS disease mechanisms and screen for drug candidates Read More »
Published February 18, 2015
Calias responsible for ERT programs and driving scientific and strategic direction Read More »
Published February 17, 2015
Will house commercial, corporate analytics, and business development staff Read More »
Published February 13, 2015
Expands translational oncology drug discovery services Read More »
Published February 12, 2015
Jayaraman and Kemmerling take on Discovery and Preclinical roles Read More »
Published February 6, 2015
To generate bispecific molecules against multiple targets Read More »
Published February 3, 2015
Foehr brings more than 20 years of pharma experience Read More »
Published February 2, 2015
Advances MS Research Read More »
By Adele Graham-King, Contributing Editor
Published January 29, 2015
To use or not to use unlicensed drugs? That is the question. Read More »
Published January 22, 2015
Will research and develop approaches to CAR T cell therapy in cancer Read More »
Published January 20, 2015
Aims to improve asset development and delivery timelines Read More »
Published January 19, 2015
To apply discovery and technology platforms to develop inhibitors for addictive disorders Read More »
Published January 14, 2015
Gains exclusive rights to oncology target Read More »
Published January 12, 2015
Will include additional oncology targets Read More »
Published January 9, 2015
Aims to identify new treatment approaches for diseases with significant unmet need Read More »
Published January 9, 2015
Includes cross-license for two programs targeting thrombosis and cardiovascular disease Read More »
Published January 9, 2015
X-Chem will apply its discovery engine to identify novel compounds Read More »
Published January 5, 2015
To develop antisense drugs to treat gastrointestinal autoimmune disorders Read More »
Published December 17, 2014
Includes a series of small molecule compounds against a cardiovascular drug target Read More »
Published December 15, 2014
Broadens access to key biotech hubs Read More »
Published December 11, 2014
X-Chem to identify drug candidates against Alexion targets Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On